Physician profile
Dan H Shell
NPI 1043316821
$2,553.16
in general payments reported to CMS, 2019-2025
14 companies · $82.15 in 2025
The $82.15 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.14 · 2020: $205 · 2021: $1,582 · 2022: $179 · 2023: $310 · 2024: $164 · 2025: $82.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $556.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,567.57 | 2019-2021 | |
| Biotissue Holdings INC. | $297.27 | 2023-2024 | |
| Aroa Biosurgery Incorporated | $211.48 | 2022-2023 | |
| Sientra, INC. | $191.45 | 2020 | |
| Kerecis Limited | $55.62 | 2023-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Surgiclose |
| Coopersurgical, INC. | $43.71 | 2022 | |
| Tela Bio, INC. | $38.29 | 2022 | |
| Acera Surgical, INC. | $31.68 | 2021 | |
| Motiva USA, LLC | $26.84 | 2025 | |
| Integra Lifesciences Corporation | $23.87 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Heron Therapeutics, INC. | $22.73 | 2022 | |
| Solventum Corporation | $15.90 | 2025 | V.A.C.Ulta, V.A.C. Veraflo Cleanse Choice |
| Smith+Nephew, INC. | $13.57 | 2019 | |
| Mentor Worldwide LLC | $13.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Shell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.